Osteoarthritis: The Challenge of Establishing a Personalised Treatment

Chairpeople:

Johanne Martel-Pelletier,¹ Antonello Pietrangelo²

Speakers:

Francis Berenbaum,³ Jean-Pierre Pelletier,⁴ Burkhard Leeb⁵

1. Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Canada 
2. Unit of Internal Medicine and Metabolic Diseases, Centre for Hemochromatosis University Hospital, Modena, Italy 
3. University Pierre & Marie Curie, INSERM UMR-S938, AP-HP Saint-Antoine Hospital, Paris, France 
4. Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Canada
5. 2 nd Department of Medicine, Centre for Rheumatology, Lower Austria, State Hospital Stockerau, Karl Landsteiner Institute for Clinical Rheumatology, Stockerau, Austria

Disclosure:

J. Martel-Pelletier: shareholder of ArthroLab Inc. and consultant for AbbVie, Bioiberica, Merck & Co, Servier, and TRB Chemedica. A. Pietrangelo has not declared any disclosure. F. Berenbaum: consultant for Pfizer, Expanscience, Servier (and research grant), Sanofi, and AbbVie, and symposia for Rottapharm, IBSA, Genevrier, Bioiberica, and TRB Chemedica (and research grant). J-P. Pelletier: shareholder of ArthroLab Inc. and consultant for Bioiberica, Elanco, Endocyte, Ferring, Merck & Co, Pfizer, Servier, and TRB Chemedica. B. Leeb: participated in clinical trials sponsored by IBSA, Servier, Tropon, and received honoraria from IBSA, TRB Chemedica, Servier,CSC, Sanova, Bayer, Lacer, Fidia.

Acknowledgements:

Writing assistance provided by Dr Tom Priddle.

Support:

The publication of this article was funded by TRB Chemedica International SA. The views and opinions expressed are those of the authors and not necessarily of TRB Chemedica International SA.

Citation:

EMJ Rheumatol. 2014;1[1]:33-39. DOI/10.33590/emjrheumatol/10312199. https://doi.org/10.33590/emjrheumatol/10312199.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.